Ferulic acid / PKM2 Cancer Research Results

FA, Ferulic acid: Click to Expand ⟱
Features:
Ferulic acid is an antioxidant found in some skin creams and serums.
Foods: popcorn, bamboo, whole-grain rye bread, whole-grain oat flakes, sweet corn (cooked)
Ferulic acid (FA) is a hydroxycinnamic acid abundant in plant cell walls (notably cereals/whole grains) with strong antioxidant and cytoprotective activity. Mechanistically, FA is frequently described as inducing Nrf2/HO-1 antioxidant programs and suppressing NF-κB-linked inflammation, with additional model-dependent anticancer effects (cell-cycle arrest, apoptosis, reduced invasion). Oral exposure is variable because FA is rapidly metabolized (often as conjugates) and bioaccessibility depends on the food matrix.

-Ferulic acid found in dietary strand fractions, especially its free form, has important functions for protecting the human health.
-AChE inhibitor (AD)
-Cooking results in an increase in free ferulic acid quantity and in a reduction in bound ferulic acid quantity.
Bamboo shoots       243.6 mg/100g
Sugar-beet pulp     800 mg/100g
Popcorn             313 mg/100g
Wheat bran	    500–1500mg/100g
Whole wheat flour   100–300mg/100g
            
Type of corn p-coumaric acidferulic acid
   mg/kg, DW mg/kg, DW
Yellow dent 18.9 265
American blue N.D. 927
Mexican blue 1.3 202
white 6.6 2484
Pathway / Target	Modulation by FA / Direction
Aβ aggregation	         ↓ Inhibits fibril formation and destabilizes existing Aβ fibrils 
BACE‑1 & APP	         ↓ Reduces BACE-1 and APP expression; ↑ MMP‑2/‑9 expression promoting Aβ clearance
Tau hyperphosphorylation  Implicitly ↓ through modulation of Ca²⁺/CDK5/GSK3β pathways
Ca²⁺         	         ↓ FA lowers STEP levels via chelation of Ca²⁺, suppressing PP2B → restores synaptic plasticity
(AChE / BChE)	         ↓ Inhibition of AChE (FA IC₅₀~15 µM, derivatives IC₅₀ down to 0.006 µM); also BChE
(MAO‑A/B)	         ↓ Inhibits MAO‑B (derivatives IC₅₀ ~0.3–0.7 µM), reducing ROS
ROS                      ↓ Scavenges ROS, enhances antioxidant enzymes (e.g., catalase), ↓ MDA
(COX‑2, 5‑LOX, NLRP3)	 ↓ Derivatives inhibit COX‑2/5‑LOX; derivative 13a ↓ NLRP3 inflammasome
Iron/Cu²⁺ chelation	 ↓ Metal-induced Aβ aggregation via chelation by FA and derivatives
Autophagy & Aβ clearance  ↗ Suggested promotion of autophagy mechanisms targeting Aβ
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Nrf2 → HO-1 / ARE antioxidant response Stress adaptation modulation (context-dependent) Nrf2 ↑; HO-1 ↑; antioxidant defenses ↑ R, G Endogenous antioxidant upshift FA is repeatedly reported to promote Nrf2 nuclear translocation and HO-1 induction; this is one of the most defensible “core” mechanisms.
2 NF-κB inflammatory transcription (COX-2 / iNOS / cytokines) NF-κB ↓; COX-2/iNOS and pro-inflammatory cytokine programs ↓ (reported) Inflammation tone ↓ (tissue protective) R, G Anti-inflammatory signaling Often described as downstream of redox changes and upstream of reduced inflammatory mediators; direction is consistent across many inflammation models.
3 ROS / oxidative stress tone Oxidative stress ↓ (often); ROS direction can vary by tumor model Oxidative injury ↓ P, R, G Redox buffering (context-dependent) FA is classically antioxidant; in tumor systems, effects may be secondary to signaling changes and vary with baseline redox instability.
4 Cell-cycle control (Cyclin D1 / CDK4/6; checkpoints) Cell-cycle arrest ↑ (reported); Cyclin D1 ↓; proliferation ↓ G Cytostasis Frequently reported as later phenotype-level outcomes; direction and checkpoint phase (G1 vs G2/M) vary by model.
5 Apoptosis (intrinsic caspase-linked; p53 axis in some models) Apoptosis ↑; caspase activation ↑ (reported); p53/p21 ↑ (model-dependent) ↔ (generally less activation) G Cell death execution Apoptosis is commonly observed in cancer models but is not as “signature-direct” as for mitochondrial toxins; best treated as downstream/conditional.
6 MAPK re-wiring (ERK / JNK / p38) MAPK modulation (context-dependent) P, R, G Signal reprogramming MAPK direction depends on whether FA is acting primarily as anti-inflammatory/anti-stress vs antiproliferative; avoid hard arrows for p38/JNK/ERK unless model-specific.
7 PI3K → AKT (± mTOR) survival axis PI3K/AKT modulation (reported; model-dependent) R, G Survival/growth modulation Often listed in anticancer summaries; treat as “reported” rather than universal primary mechanism.
8 Invasion / metastasis programs (MMPs / migration) MMPs ↓; migration/invasion ↓ (reported) G Anti-invasive phenotype Observed as later outcomes (gene expression + phenotype assays) and commonly linked to NF-κB/MAPK context.
9 Radiation/chemo injury mitigation (supportive care framing) Adjunct potential: may reduce treatment-associated oxidative/inflammatory injury (context) Tissue protection ↑ (reported) G Cytoprotection Animal models report radioprotective/anti-inflammatory effects; present as supportive/adjunct rather than standalone anticancer therapy.
10 Bioavailability / metabolism constraint (conjugation; food-matrix dependence) Systemic exposure variable; much appears as glucuronide/sulfate conjugates Translation constraint FA is absorbed and rapidly metabolized; “bioavailability” varies widely with food matrix and binding to polysaccharides in grains.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (primary/rapid effects; early redox interactions / rapid signaling shifts)
  • R: 30 min–3 hr (acute stress-response + transcription signaling shifts)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)


PKM2, Pyruvate Kinase, Muscle 2: Click to Expand ⟱
Source:
Type: enzyme
PKM2 (Pyruvate Kinase, Muscle 2) is an enzyme that plays a crucial role in glycolysis, the process by which cells convert glucose into energy. PKM2 is a key regulatory enzyme in the glycolytic pathway, and it is primarily expressed in various tissues, including muscle, brain, and cancer cells.
-C-myc is a common oncogene that enhances aerobic glycolysis in the cancer cells by transcriptionally activating GLUT1, HK2, PKM2 and LDH-A
-PKM2 has been shown to be overexpressed in many types of tumors, including breast, lung, and colon cancer. This overexpression may contribute to the development and progression of cancer by promoting glycolysis and energy production in cancer cells.
-inhibition of PKM2 may cause ATP depletion and inhibiting glycolysis.
-PK exists in four isoforms: PKM1, PKM2, PKR, and PKL
-PKM2 plays a role in the regulation of glucose metabolism in diabetes.
-PKM2 is involved in the regulation of cell proliferation, apoptosis, and autophagy.
– Pyruvate kinase catalyzes the final, rate-limiting step of glycolysis, converting phosphoenolpyruvate (PEP) to pyruvate with the production of ATP.
– The PKM2 isoform is uniquely regulated and can exist in both highly active tetrameric and less active dimeric forms.
– Cancer cells often favor the dimeric form of PKM2 to slow pyruvate production, thereby accumulating upstream glycolytic intermediates that can be diverted into anabolic pathways to support cell growth and proliferation.
– Under low oxygen conditions, cancer cells rely on altered metabolic pathways in which PKM2 is a key player. – The shift to aerobic glycolysis (Warburg effect) orchestrated in part by PKM2 helps tumor cells survive and grow in hypoxic conditions.

– Elevated expression of PKM2 is frequently observed in many cancer types, including lung, breast, colorectal, and pancreatic cancers.
– High levels of PKM2 are often correlated with enhanced tumor aggressiveness, poor differentiation, and advanced clinical stage.

PKM2 in carcinogenesis and oncotherapy

Inhibitors of PKM2:
-Shikonin, Resveratrol, Baicalein, EGCG, Apigenin, Curcumin, Ursolic Acid, Citrate (best known as an allosteric inhibitor of phosphofructokinase-1 (PFK-1), a key rate-limiting enzyme in glycolysis) potential to directly inhibit or modulate PKM2 is less well established

Full List of PKM2 inhibitors from Database
-key connected observations: Glycolysis↓, lactateProd↓, ROS↑ in cancer cell, while some result for opposite effect on normal cells.
Tumor pyruvate kinase M2 modulators

Flavonoids effect on PKM2
Compounds name IC50/AC50uM Effect
Flavonols
1. Fisetin 0.90uM Inhibition
2. Rutin 7.80uM Inhibition
3. Galangin 8.27uM Inhibition
4. Quercetin 9.24uM Inhibition
5. Kaempferol 9.88uM Inhibition
6. Morin hydrate 37.20uM Inhibition
7. Myricetin 0.51uM Activation
8. Quercetin 3-b- D-glucoside 1.34uM Activation
9. Quercetin 3-D -galactoside 27-107uM Ineffective
Flavanons
10. Neoeriocitrin 0.65uM Inhibition
11. Neohesperidin 14.20uM Inhibition
12. Naringin 16.60uM Inhibition
13. Hesperidin 17.30uM Inhibition
14. Hesperitin 29.10uM Inhibition
15. Naringenin 70.80uM Activation
Flavanonols
16. (-)-Catechin gallateuM 0.85 Inhibition
17. (±)-Taxifolin 1.16uM Inhibition
18. (-)-Epicatechin 1.33uM Inhibition
19. (+)-Gallocatechin 4-16uM Ineffective
Phenolic acids
20. Ferulic 11.4uM Inhibition
21. Syringic and 13.8uM Inhibition
22. Caffeic acid 36.3uM Inhibition
23. 3,4-Dihydroxybenzoic acid 78.7uM Inhibition
24. Gallic acid 332.6uM Inhibition
25. Shikimic acid 990uM Inhibition
26. p-Coumaric acid 22.2uM Activation
27. Sinapinic acids 26.2uM Activation
28. Vanillic 607.9uM Activation


Scientific Papers found: Click to Expand⟱
1654- FA,    Molecular mechanism of ferulic acid and its derivatives in tumor progression
- Review, Var, NA
AntiCan↑, Inflam↓, RadioS↑, ROS↑, Apoptosis↑, TumCCA↑, TumCMig↑, TumCI↓, angioG↓, ChemoSen↑, ChemoSideEff↓, P53↑, cycD1/CCND1↓, CDK4↓, CDK6↓, TumW↓, miR-34a↑, Bcl-2↓, Casp3↑, BAX↑, β-catenin/ZEB1↓, cMyc↓, Bax:Bcl2↑, SOD↓, GSH↓, LDH↓, ERK↑, eff↑, JAK2↓, STAT6↓, NF-kB↓, PYCR1↓, PI3K↓, Akt↓, mTOR↓, Ki-67↓, VEGF↓, FGFR1↓, EMT↓, CAIX↓, LC3II↑, p62↑, PKM2↓, Glycolysis↓, *BioAv↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

GSH↓, 1,   PYCR1↓, 1,   ROS↑, 1,   SOD↓, 1,  

Mitochondria & Bioenergetics

FGFR1↓, 1,  

Core Metabolism/Glycolysis

CAIX↓, 1,   cMyc↓, 1,   Glycolysis↓, 1,   LDH↓, 1,   PKM2↓, 1,  

Cell Death

Akt↓, 1,   Apoptosis↑, 1,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,  

Autophagy & Lysosomes

LC3II↑, 1,   p62↑, 1,  

DNA Damage & Repair

P53↑, 1,  

Cell Cycle & Senescence

CDK4↓, 1,   cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

EMT↓, 1,   ERK↑, 1,   miR-34a↑, 1,   mTOR↓, 1,   PI3K↓, 1,   STAT6↓, 1,  

Migration

Ki-67↓, 1,   TumCI↓, 1,   TumCMig↑, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature

angioG↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling

Inflam↓, 1,   JAK2↓, 1,   NF-kB↓, 1,  

Hormonal & Nuclear Receptors

CDK6↓, 1,  

Drug Metabolism & Resistance

ChemoSen↑, 1,   eff↑, 1,   RadioS↑, 1,  

Clinical Biomarkers

Ki-67↓, 1,   LDH↓, 1,  

Functional Outcomes

AntiCan↑, 1,   ChemoSideEff↓, 1,   TumW↓, 1,  
Total Targets: 46

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance

BioAv↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: PKM2, Pyruvate Kinase, Muscle 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:77  Target#:772  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page